Loading
Diabetes Treatment and Management · Journal article
Archives of Medical Science · August 2, 2026
Early or partial results. Treat as a signal, not a conclusion.
This meta-analysis synthesized 41 studies but could pool only 2 retrospective cohorts examining GLP-1 receptor agonists and tendon outcomes, both from total shoulder arthroplasty populations. The pooled odds ratio for surgical revision was 0.71 (95% CI: 0.59–0.85) with no heterogeneity, but the evidence base is narrow, uses an indirect endpoint, and the authors themselves characterise the finding as 'evidentially thin'.
Systematic review and meta-analysis of retrospective cohorts. Patients in retrospective cohorts undergoing total shoulder arthroplasty and treated with GLP-1 receptor agonists; broader tendon pathology populations identified but not poolable.. Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1RAs). Compared with: Comparator group (not specified in source text; assumed usual care or no GLP-1RA use).
773 records screened; 41 studies synthesized; only 2 retrospective cohorts poolable from 6 identified Pooled odds ratio for revision in total shoulder arthroplasty: 0.71 (95% CI: 0.59–0.85) Heterogeneity (I²) = 0%, indicating statistical consistency between the two studies
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The finding is too narrow and indirect to guide clinical practice regarding GLP-1 receptor agonists for tendon protection or healing. Clinicians should await larger, prospective studies with direct tendon outcomes before relying on this evidence.
A meta-analysis of only two poolable retrospective cohorts with a surrogate endpoint (surgical revision) in a narrow population (total shoulder arthroplasty), lacking direct evidence on tendon healing or rupture prevention in broader clinical use.
As stated by the source record.
Quoted from the source exactly as published.
The finding is too narrow and indirect to guide clinical practice regarding GLP-1 receptor agonists for tendon protection or healing. Clinicians should await larger, prospective studies with direct tendon outcomes before relying on this evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tendinopathy and tendon rupture occupy an odd position in cardiovascular (CV) medicine: formally recognised as adverse events of special interest (AESI) in contemporary lipid trials, and routinely adjudicated within them, yet almost never discussed at cardiology meetings.The systematic review and meta-analysis by Khayyat and Khayyat in the current 4/2026 issue of Archives of Medical Science [1] approaches the tendon from the opposite direction, asking whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote its healing.Their answer is cautious, and appropriately so.The question their work opens is considerably larger, and it belongs to lipidology. What the meta-analysis establishes, and where it stopsThe authors screened 773 records and synthesized 41.Of six retrospective cohorts, only two -both in total shoulder arthroplasty -proved poolable, yielding an odds ratio for revision of 0.71 (95% CI: 0.59-0.85)with I² = 0% [1].The estimate is statistically tidy and evidentially thin: two administrative database analyses, standing alongside a
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.